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We evaluated a relationship between nitric oxide plasma correlation and insulin resistance in white coat hypertensive patients.
Patients were screened for white coat hypertension using an ambulatory blood pressure monitoring. The homeostasis model
assessment insulin resistance index (HOMA-IR) was used to assess insulin resistance, and plasma nitrate concentrations were
determined by chemiluminescence. The HOMA-IR was signiﬁcantly higher in hypertensive (3.84 ± 0.62) when compared to
white coat (2.11 ± 0.36) and normotensive (1.40 ± 0.21). We found no correlation between HOMA-IR and plasma nitrate levels
in all three groups. We suggest that the more important issue for these patients is to focus on the metabolic abnormalities where
lifestyle interventions such as weight control and exercise have proven eﬀective.
Copyright © 2009 L. M. Marchi-Alves and E. C. Carnio. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Insulin resistance plays a role in type 2 diabetes and
is close related with public health problems, as obesity,
dyslipidemias, coronary artery disease, hypertension, and a
bunch of metabolic and cardiovascular malfunction which
is deﬁned as metabolic syndrome. Insulin resistance is an
alteration in the action of insulin since besides the normal
levels of insulin it cannot trigger the signal for glucose
absorption. The eﬀects of this condition can have profound
pathophysiologic eﬀe c t so nv a r i o u so r g a n sa n dt i s s u e so f
the body. The clinical consequences, beyond hypertension,
include hyperglycemia-induced tissue damage, dyslipidemia,
metabolic syndrome, and cardiovascular disease [1].
Endothelium has many diﬀerent roles including the
regulation of blood-tissue permeability and vascular tonu,
and control of vascular surface properties for during inﬂam-
mation. Nitric oxide (NO) is a gaseous modulator, which
actsinregulationofendothelialfunctions.AnNOdeﬁciency,
which is also known as endothelial dysfunction, is the ﬁrst
step for the occurrence of many diseases including heart
failure, diabetes mellitus, dyslipidemia, insulin resistance,
and hypertension [2].
White coat hypertension is a well-known clinical situ-
ation deﬁned as a persistently elevated blood pressure in
the physician’s oﬃce, even though the blood pressure is
normal in other situations, and its prognostic signiﬁcance
remains controversial [3, 4]. Whether individuals with WCH
have an abnormal autonomic-cardiac regulation similar to
that observed in sustained hypertensive patients is unknown,
and in subjects with white coat hypertension it is unclear
whether ambulatory blood pressure progresses over time
and exhibits an increased cardiovascular risk. Additionally, it
remains unclear whether white coat hypertension is already
associated with vascular end-organ damage.
Some reports have suggested that white coat hyper-
tension might be associated with someof these metabolic
disturbances, instead of white coat hypertension per se,
that may potentially explain the greater extent of end-organ
damage sometimes observed in white coat hypertension
patients when compared with normotensive individuals
[5].
The combination of insulin resistance and compensatory
hyperinsulinemia increases the likelihood that an individual
will be hypertensive. Given the rapid increase in the number
of clinical syndromes and abnormalities associated with2 Cardiology Research and Practice
insulin resistance/hyperinsulinemia, it seems reasonable to
suggest that the cluster of these changes could be related to
the defect in insulin action, which can be subsumed under
the term of the insulin resistance syndrome. In addition to
the identiﬁcation of additional clinical syndromes related
to insulin resistance/hyperinsulinemia, a number of new
risk factors have been recognized that would increase
cardiovascular risk in these individuals. Evidence is also
accumulating that sympathetic nervous system activity is
increased in insulin resistant, hyperinsulinemic individuals,
and, along with the salt sensitivity associated with insulin
resistance/hyperinsulinemia, increases the likelihood that
these individuals will develop essential hypertension [6].
The ability of insulin to stimulate glucose disposal varies
more than sixfold in apparently healthy individuals [7].
Overweight and obesity are highly associated with mul-
tiple comorbidities, such as elevated blood pressure values,
dyslipidaemia, reduced insulin sensitivity, and alterations of
large and minor vessels. Abdominal obesity is a risk factor
for cardiovascular disease worldwide, and it is becoming a
dramatic issue for national health systems [8].
The more overweight/obese the persons are, the more
likely they are to be insulin-resistant and at increased
risk of cardiovascular disease, but substantial numbers of
overweight/obese individuals remain insulin-sensitive, and
not all insulin-resistant persons are obese. Of greater clinical
relevance is evidence that the metabolic beneﬁt and decrease
in risk of cardiovascular disease following weight loss occurs
primarily in those overweight/obese individuals that are also
insulin-resistant [6].
On the other hand, cardiovascular diseases are the
most common causes of deaths, particularly in developed
countries, and most are related with HT. Thus, BP control
is the basis for the prevention of cardiovascular death.
However, the diagnosis and management of hypertension is
diﬃcult due to the fact that BP varies greatly depending on
physical and mental stresses [9].
Insulin resistance, obesity, and endothelial dysfunction
are observed in some patients suﬀering from hypertension.
It remains unclear whether patients with white coat hyper-
tension elude the risk of this condition; so in this study we
evaluated a relationship between nitrate plasma correlation
and insulin resistance in white coat hypertension patients.
2.MaterialsandMethods
2.1. Subjects. Based on BP measurements at the medi-
cal oﬃce and on Ambulatory Blood Pressure Monitoring
(ABPM), the patients were divided into the following
categories: (a) sustained hypertension—systolic BP at the
medical oﬃce ≥140mmHg or diastolic BP ≥90mmHg, or
both, and mean of systolic and diastolic BP on ABPM
duringthewakefulnessperiod≥135mmHgand≥85mmHg,
respectively; (b) white coat hypertension—systolic BP at
the medical oﬃce ≥140mmHg or diastolic BP ≥90mmHg,
or both, and mean of systolic and diastolic BP on ABPM
during the wakefulness period <135mmHg and <85mmHg,
respectively; (c) normotension—systolic BP at the medical
oﬃce <140mmHg and diastolic BP <90mmHg, and mean
of systolic and diastolic BP on ABPM during the wakefulness
period <135mmHg and <85mmHg, respectively.
Exclusion criteria for entry in the study were proceeding
from the pediatric clinic, pregnant patients, insulin using
diabetics, and patients with devastating illnesses including
malignancies, renal failure, liver diseases, and heart failure.
The procedures followed were in accordance with the
ethical standards of the responsible committee on human
experimentation and with the Helsinki Declaration and were
approved by the Institutional Review Committee. Subjects
gave informed consent. Study population came from the
same geographic area.
2.2. Oﬃce BP Measurements. At the medical oﬃce, BP was
measured with a regularly checked automate oscillometric
device (OMRON) with an appropriate cuﬀ for the arm’s
circumference. After a 5-minute rest with the patient seated,
themeasurementsweretakenonthepatient’s barerightarm,
which was supported and maintained at the heart’s level. The
averageofthreemeasurementswastakenasthemeansystolic
and diastolic pressures.
2.3. Ambulatory BP Monitoring (ABPM). ABPM was per-
formed with an oscillometric device (SpaceLabs 90207),
which was checked monthly against a mercury column
sphygmomanometer.Themeasurementsweretakenevery15
minutes from 7:00 AM to 6:00 PM and every 30 minutes
from 6:01 PM to 6:59 AM, and the patient maintained his
usual activities throughout the day. The appropriate cuﬀ for
the arm’s circumference was placed on the no dominant
arm, and the patients were instructed to maintain their
arm stretched along their body and not to move their arm
during measurements. The recording valid for analysis had
a minimum duration of 24 hours and 80 valid readings,
corresponding to at least 80% of all measurements.
2.4.AnthropometricParameters. Theanthropometricindica-
tors were analyzed according to the criteria of World Health
Organization—WHO [10]. Anthropometric measurements
included weight, height, body mass index (BMI), and
waist circumference. Every subject’s height was measured in
centimeters while the participant stood still without shoes,
andweightwasmeasuredtothenearest0.1kgwithelectronic
weightscaleinkilogramswiththeparticipantlightlyclothed.
Subjects were categorized according to their body mass index
(BMI). BMI was calculated as weight divided by square of
height (kg/m2). Underweight was deﬁned as a BMI less than
18.5kg/m2, normal weight as 18.5–24.9, overweight as 25–
29.9kg/m2, and obesity as a BMI of 30.0kg/m2 or greater.
Waist circumference (WC) was measured in centimeters at
the midpoint between the bottom of the ribs and the top
of the iliac crest. The cutoﬀ points for cardiovascular disease
risk was 102cm for men and 88 for women.
2.5. Laboratory Methods. Subjects reported to the labora-
tory between 07:00 and 09:00 A.M., rested quietly for 10
minutes in the supine position, and a blood sample for theCardiology Research and Practice 3
Table 1: Clinical characteristics of normotensive (NT), hypertensive (HT), and white coat hypertensive (WCH) patients.
NTs (n = 22) HTs (n = 22) WCHs (n = 20)
Clinic Systolic BP (mmHg) 114.9 ± 2.8 154.2 ± 3.1‡ 142.1 ± 1.75‡§
Clinic Diastolic BP (mmHg) 76.1 ± 0.8 98.6 ± 2.1‡ 90.21 ±3.4‡§
Ambulatory Systolic BP (mmHg) 102.9 ± 8.5 143.9 ± 3.9‡ 118.5 ± 1.4‡#
Ambulatory Diastolic BP (mmHg) 71.79± 1.24 92.21 ± 3.0‡ 75.78 ± 1.44‡#
Age (years) 43.95 ± 2.66 49.14 ± 3.42 44.07 ± 3.39
BMI (kg/m2) 24.40 ± 0.73 29.13 ± 1.02‡ 28.21 ± 0.73†
WC (cm) 0.86 ± 0.02 0.92 ± 0.02† 0.89 ± 0.02
∗P<. 05 ×NTs; †P<. 01 ×NTs, ‡P<. 001 ×NTs, §P<. 05 ×HTs, #P<. 001 ×HTs.
determination of glucose and insulin was obtained from an
antecubital vein and collected into a speciﬁc tube. Blood
samples were drawn after a fasting period of 12 hours at the
same time of the day. Serum collected was sent to a certiﬁed
medical laboratory for subsequent analysis using automated
enzymatic procedures with calculated precision values <3%.
An estimation of insulin resistance was calculated using the
homeostasis model analysis (HOMA-IR) using the formula:
glucose (mU/L) × [insulin (pmol/L)/22.5] [11].
Blood samples for nitrate determination were cen-
trifuged immediately at 3000g for 15 minutes, and super-
natant wascollectedandfrozenat −20◦C until assayed.Since
NO is stoichiometrically converted to nitrate and nitrite, the
levels of the NO produced in a response can be tracked
by assaying for nitrate and nitrite. The NO levels were
measured after enzymatic conversion of all nitrate to nitrite.
Fasting peripheral venous blood samples for nitrate were
collected into heparinized vacutainer tubes. Plasma samples
were isolated by 2500g centrifugation at 4◦Cf o r1 0m i n u t e s .
Allplasmasampleswerekeptat −70◦Cuntiltheexperiments
were performed.
On the day of the assay, plasma samples were thawed
and deproteinized with 95% ethanol (at 4◦C) for 30 minutes,
subsequently centrifuged, and the supernatant was used
for measurement of nitrate according to the NO/ozone
chemiluminescence technique as previously described by
Archer [12], using a Sievers NO Analizer (Sievers 280 NOA;
Sievers, Boulder, CO). Sodium nitrate (Sigma Chemical) was
used as a standard reference.
2.6. Statistical Method. The values of the selected variables
were deﬁned as mean ± SD. The NO values of the groups
(normotensive, hypertensive, and white coat hypertensive)
were compared with one-way ANOVA (Tukey HSD). “P”
values <.05 were considered statistically signiﬁcant. Pearson
correlation analysis was used to ﬁnd out the correlations
between HOMA-IR and nitrate plasma concentration.
3. Results
In this study 71 patients were screened for white coat
hypertension, of which 64 were included in the study.
The study group consisted of 20 subjects with white coat
hypertension (30% male and 70% female patients), 22
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Figure 1: Fasting glucose levels (mg/dL) in normotensive (NT),
sustained hypertensive (HT), and white coat hypertensive (WCH)
patients. ‡P<. 001, ∗P<. 05.
hypertensives (68.2% male and 31.8% female patients), and
22normotensiveparticipants(31.8%maleand68.2%female
patients).
Clinical characteristics of subjects of the three groups are
listed in Table 1. From the total 27.27% of normotensives,
31.82% of hypertensives and 28.57% of white coat hyperten-
sives were overweight. The occurrence of obesity was 9.09%
of normotensives, 50.62% of hypertensives, and 14.28% of
white coat hypertensives.
Plasma glucose levels of the three groups are shown
in Figure 1. The HTs (95.0 ± 3.26mg/dL) and white
coat hypertensives (90.07 ± 3.72mg/dL) had signiﬁcantly
higher levels of glucose than the normotensives (78.14 ±
2.05mg/dL). No signiﬁcant diﬀerence was observed between
white coat hypertensives and hypertensives regarding these
parameters.
Figure 2 shows fasting plasma insulin concentrations in
all three groups tested. There was a statistically signiﬁcant
diﬀerence (P<. 01) between the hypertensive group
(17.10 ± 0.91μU/mL) and the normotensive group (6.99 ±
0.91μU/mL). In addition, there was no signiﬁcant diﬀerence
regarding fasting plasma insulin concentrations between4 Cardiology Research and Practice
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Figure 2: Fasting insulin levels (μU/ml) in normotensive (NT),
sustained hypertensive (HT), and white coat hypertensive (WCH)
patients. †P<. 01.
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Figure 3:HOMA-IRinnormotensive(NT),sustainedhypertensive
(HT),andwhitecoathypertensive(WCH)patients. ‡P<. 001, ∗P<
.05.
the white coat hypertensives (9.73 ± 1.68μU/mL) and the
normotensives or hypertensives groups.
The HOMA-IR values in the groups are demonstrated in
Figure 3. The values was signiﬁcantly higher in hypertensives
(3.84 ± 0.62) when compared to white coat hypertensives
(2.11 ± 0.36) and normotensives (1.40 ± 0.21). There were
no signiﬁcant diﬀerences between white coat hypertensives
and normotensives.
Figure 4 shows the correlation between HOMA-IR and
nitrate plasma concentration. We found no correlation
between HOMA-IR and plasma nitrate levels in all three
diﬀerent groups.
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Figure 4: Relationship between HOMA and plasma nitrate levels
innormotensive(NT),sustainedhypertensive(HT),andwhitecoat
hypertensive (WCH) patients.
4. Discussion
The results of this study demonstrate a normal insulin
resistance in white coat hypertensive patients.
Although the white coat hypertensive group had similar
fasting insulin levels compared with normotensive group,Cardiology Research and Practice 5
careful inspection of their data shows that their white coat
hypertension population had characteristics of the metabolic
syndrome (increased body mass index and fasting glucose
level), which were also present in patients with sustained
hypertension.
Although the majority of individuals in the general
population that can be considered insulin resistant are
also overweight/obese, not all overweight/obese persons are
insulin resistant. Of greater clinical relevance is the fact
that signiﬁcant improvement in these metabolic abnormal-
ities following weight loss is seen only in the subset of
overweight/obese individuals that are also insulin resistant.
In view of the large number of overweight/obese subjects
at potential risk to be insulin resistant/hyperinsulinemic
(and at increased cardiovascular risk), and the diﬃculty in
achieving weight loss, it seems essential to identify those
overweight/obese individuals who are also insulin resistant
and will beneﬁt the most from weight loss, then target this
population for the most-intensive eﬀorts to bring about
weight loss [7].
In relation to results of HOMA IR, researchers assumed
diﬀerent methods to describe a threshold, such as the top
quintile and 90th percentile of the HOMA in normal glucose
tolerant nonobese populations. Considering the patients
whose HOMA-IR is above the 90th percentile as insulin
resistant subjects, Geloneze et al. [13] found a threshold
value for insulin resistance of 2.71. In accordance with these
criteria, inside of this proposal, our ﬁndings determine that
the insulinoresistance is present in the carriers of essential
hipertensive and normotensive individuals a presence of
indices of normality in the evaluation of this parameter. But,
in interesting way, when we evaluate the group white coat
hypertension, even so let us not ﬁnd statistically diﬀerence
between normotension, we observe raised indices, that do
not allow to ﬁt them in the category of normoglycemics
[13]. However, to validate the potential use of HOMA-IR
values in clinical practice, it is important to establish its
distribution in a sample of normoglycemic individuals from
a population with the same genetic background [14]. In this
regard, Ghiringhello et al. [15] describe the distribution of
HOMA-IR values in a large sample of Brazilian population
(1.2±0.65paraIMC < 25,1.8±0.98paraIMC=25–30e2.9±
1.6p a r aI M C> 30). Therefore, if we calculated the HOMA-
IR threshold in those subjects who fulﬁlled this criteria, we
would ﬁnd that the essential hypertensive subjects as well as
the white coat hypertensives present a higher index than that
observed at the normal criteria, having had to be categorized
as insulin-resistant. That is, if we considered this criterion
of deﬁnition for insulin-resistance determination, the results
point that the insulin resistance is deﬁnitively installed in
white coat hypertension [15].
Although stated that the white coat hypertension group
had similar fasting insulin and HOMA-IR results, compared
to normotensives, careful inspection of our data shows that
their white-coat hypertension population had characteristics
of the insulin-resistance syndrome: elevated body mass
index,fastingglucoselevels,andestimated insulinresistance.
Thus, we agree to previous studies that they indicate a
possible relationship between end-organ damage and insulin
resistanceinpatients withwhitecoathypertensionexists [16,
17]. The association between white-coat hypertension and
metabolic disturbances of insulin-resistance syndrome may
help explain the high prevalence of cardiovascular disease
often associated with white coat hypertension [18–20].
White coat hypertension and metabolic abnormalities
characteristic of insulin-resistance syndrome coexist, and in
which the increased risk of target organ damage is deter-
mined not by the BP, but by the metabolic abnormalities.
This distinction would account for some previous ﬁndings
of increased target organ damage in white coat hypertension
[20].
5. Conclusions
White coat hypertension should preferentially be accepted
as an alarming sign of excess weight and many associated
disorders in the future, rather than just being considered
a predisposing factor of hypertensive or atherosclerosis
alone [21]. There are limitations in this study, which was
conducted on a small sample of patients, and the subjects are
relatively young with no inclusion criteria. Thus, although
no hypertension-related target organ damage was detected
in the present study, white coat hypertension cannot be
regarded as a benign phenomenon because these subjects
displaymetabolicabnormalitiesthatarepowerfulriskfactors
for future atherosclerotic events. So in conclusion we suggest
that the more important issue for the patients is to focus
on the metabolic abnormalities related to the insulin-
resistance syndrome where lifestyle interventions such as
weight control and exercise have proven eﬀective. However
wefailtoprovethatitcouldbeapossibleinteractionbetween
a decreased NO bioavailability, endothelial dysfunction,
and the development of insulin resistance in white coat
hypertensive patients.
Arterial hypertension remains a devastating disease.
All current medical therapy is expensive, complex and
largely palliative. The management of hypertensive patients
requires co-ordination between the patient, their support
system, and healthcare professionals. Contemporary practice
requires responsibility and a role in the primary prevention,
detection and treatment of hypertension [22]. Healthcare
professionals need to combine scientiﬁc knowledge and
practice to determine the prognosis and treatment of white
c o a th y p e r t e n s i o n ,i na ne ﬀort to provide the highest quality
care to the patient [23].
References
[1] P. S. Jellinger, “Metabolic consequences of hyperglycemia and
insulin resistance,” Clinical Cornerstone, vol. 8, supplement 7,
pp. S30–S42, 2007.
[2] K. Bian, M. F. Doursout, and F. Murad, “Vascular system: role
of nitric oxide in cardiovascular diseases,” Journal of Clinical
Hypertension, vol. 10, no. 4, pp. 304–310, 2008.
[3] Y. Karter, A. Curgunlu, S. Altinis ¸ik, et al., “Target organ
damage and changes in arterial compliance in white coat
hypertension. Is white coat innocent?” Blood Pressure, vol. 12,
no. 5-6, pp. 307–313, 2003.6 Cardiology Research and Practice
[4] J. J. Polonia, G. M. Gama, J. A. Silva, C. Amaral, L. R.
Martins,andS.E.Bertoquini,“Sequentialfollow-upclinicand
ambulatorybloodpressureevaluationinalowriskpopulation
of white-coat hypertensive patients and in normotensives,”
Blood Pressure Monitoring, vol. 10, no. 2, pp. 57–64, 2005.
[5] G. Mul` e, E. Nardi, S. Cottone, et al., “Metabolic syndrome in
subjects with white-coat hypertension: impact on left ventric-
ular structure and function,” Journal of Human Hypertension,
vol. 21, no. 11, pp. 854–860, 2007.
[6] G. Reaven, “All obese individuals are not created equal: insulin
resistance is the major determinant of cardiovascular disease
in overweight/obese individuals,” Diabetes and Vascular Dis-
ease Research, vol. 2, no. 3, pp. 105–112, 2005.
[7] G. Reaven, F. Abbasi, and T. McLaughlin, “Obesity, insulin
resistance, and cardiovascular disease,” Recent Progress in
Hormone Research, vol. 59, pp. 207–223, 2004.
[8] J. Segura and L. M. Ruilope, “Obesity, essential hypertension
and renin-angiotensin system,” Public Health Nutrition, vol.
10, no. 10, pp. 1151–1155, 2007.
[ 9 ] M .E z z a t i ,A .D .L o p e z ,A .R o d g e r s ,S .V a n d e rH o o r n ,a n dC .J .
L.Murray,“Selectedmajorriskfactorsandglobalandregional
burden of disease,” The Lancet, vol. 360, no. 9343, pp. 1347–
1360, 2002.
[10] World Health Organization, “Physical status: the use and
interpretation of anthropometry. Report of a WHO Expert
Comitee,” Tech. Rep. series no 854, World Health Organiza-
tion, Geneva, Switzerland, 1995.
[11] D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F.
Treacher, and R. C. Turner, “Homeostasis model assessment:
insulin resistance and β-cell function from fasting plasma
glucose and insulin concentrations in man,” Diabetologia, vol.
28, no. 7, pp. 412–419, 1985.
[12] S. Archer, “Measurement of nitric oxide in biological models,”
FASEB Journal, vol. 7, no. 2, pp. 349–360, 1993.
[13] B. Geloneze, E. M. Repetto, S. R. Geloneze, M. A. Tambascia,
and M. N. Ermetice, “The threshold value for insulin resis-
tance (HOMA-IR) in an admixtured population. IR in the
Brazilian Metabolic Syndrome Study,” Diabetes Research and
Clinical Practice, vol. 72, no. 2, pp. 219–220, 2006.
[14] T. M. Wallace, J. C. Levy, and D. R. Matthews, “Use and abuse
of HOMA modeling,” Diabetes Care, vol. 27, no. 6, pp. 1487–
1495, 2004.
[15] M. T. Ghiringhello, J. G. H. Vieira, T. T. Tachibana, et al.,
“DistributionofHOMA-IRinBraziliansubjectswithdiﬀerent
body mass indexes,” Arquivos Brasileiros de Endocrinologia e
Metabologia, vol. 50, no. 3, pp. 573–574, 2006.
[16] A. Tunc ¸kale, S. N. Aran, H. Karpuz, and A. Dirican, “Rela-
tionship between insulin resistance and end-organ damage in
white coat hypertension,” American Journal of Hypertension,
vol. 17, no. 11, pp. 1011–1016, 2004.
[17] M. F. Muldoon, P. Nazzaro, K. Sutton-Tyrrell, and S.
B. Manuck, “White-coat hypertension and carotid artery
atherosclerosis: a matching study,” Archives of Internal
Medicine, vol. 160, no. 10, pp. 1507–1512, 2000.
[18] S. Julius, A. Mejia, K. Jones, et al., ““White coat” versus
“sustained” borderline hypertension in Tecumseh, Michigan,”
Hypertension, vol. 16, no. 6, pp. 617–623, 1990.
[19] T. E. Strandberg and V. Salomaa, “White coat eﬀect, blood
pressure and mortality in men: prospective cohort study,”
European Heart Journal, vol. 21, no. 20, pp. 1714–1718, 2000.
[20] N. Zakopoulos, C. Papamichael, H. Papaconstantinou, et al.,
“Isolated clinic hypertension is not an innocent phenomenon:
eﬀect on the carotid artery structure,” American Journal of
Hypertension, vol. 12, no. 3, pp. 245–250, 1999.
[21] M. R. Helvaci, H. Kaya, A. Yalcin, and G. Kuvandik,
“Prevalence of white coat hypertension in underweight and
overweight subjects,” International Heart Journal, vol. 48, no.
5, pp. 605–613, 2007.
[22] D. McLean, K. Kingsbury, J. A. Costello, L. Cloutier, and
S. Matheson, “Hypertension Education Program (CHEP)
recommendations: management of hypertension by nurses,”
Canadian Journal of Cardiovascular Nursing,v o l .1 7 ,n o .2 ,p p .
10–16, 2007.
[23] L. M. Alves, M. S. Nogueira, E. V. Veiga, S. de Godoy, and
E. C. Carnio, “White coat hypertension and nursing care,”
Canadian Journal of Cardiovascular Nursing,v o l .1 3 ,n o .3 ,p p .
29–34, 2003.